genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Acorda Therapeutics
Drug Discovery
StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles
Drug Discovery
StockWatch: Catalent Cuts Revenue, EBITDA Forecasts, Rattling Investors
News
FDA Extends PDUFA Date for Acorda’s Inbrija, 3 Days after Company Loses Ampyra Appeal
Industry News
After Patient Deaths, Acorda Halts Development of Parkinson’s Candidate Tozadenant
Industry News
FDA Refuses to File Acorda NDA for Inbrija
News
Insights
Industry News
Acorda Axing 20% of Workforce after 4 of 5 Ampyra Patents Invalidated
Industry News
Acorda Inhalable Parkinson’s Candidate Succeeds in Phase III Trial
Industry News
Acorda Ends Development of Plumiaz
Industry News
Acorda Acquires Biotie Therapies for $363M
1
2
3
Page 1 of 3
Scroll Up
Scroll Up
